AI Personalized Anti-Aging Platform AgeWell Receives EMA Approval: Customized Anti-Aging Plans from Genomics to Metabolomics

AI Personalized Anti-Aging Platform AgeWell Receives EMA Approval: Customized Anti-Aging Plans from Genomics to Metabolomics

On October 9, 2029, Insilico Medicine announced that its AI anti-aging platform AgeWell has received regulatory approval from the European Medicines Agency (EMA). This is the world's first approved AI-driven personalized anti-aging medical platform, marking the transition of anti-aging medicine from empirical supplementation to precision medicine.

AgeWell's workflow consists of three phases. The first phase is comprehensive biomarker collection: users provide blood samples for genomic sequencing and metabolomic analysis while wearing wearable devices that continuously collect lifestyle data including heart rate variability, sleep quality, and activity levels over a 30-day collection period.

The second phase involves the AI analysis engine's integration modeling of multidimensional data. The system compares the user's more than 400 biomarkers against a database containing the aging trajectories of 1.2 million individuals, identifying the organ systems with the fastest aging rates and their primary driving factors.

The third phase is the generation of personalized intervention plans. Plans cover nutritional supplementation, exercise prescriptions, sleep optimization, and pharmaceutical intervention when necessary. In clinical trials, subjects who followed AgeWell's intervention plan for 12 months experienced an average reversal of 2.3 years in epigenetic age.

"Aging is not a disease, but it is a common risk factor for virtually all diseases," said Insilico Medicine CEO Alex Zhavoronkov. "AgeWell's goal is not to make people immortal, but to extend healthspan — keeping people living high-quality lives for longer."

However, anti-aging medicine has long been controversial. Critics point out that current understanding of aging mechanisms remains limited, and whether so-called "epigenetic age reversal" truly means biological rejuvenation is still undetermined. Additionally, AgeWell's annual subscription fee of 5,000 euros has raised concerns about whether anti-aging technology will exacerbate health inequality.

The EMA specifically emphasized in its approval statement that AgeWell's scope of application is limited to aging management in healthy adults and is not intended for the treatment of any specific disease. The platform's clinical trials will continue to evaluate long-term safety and efficacy.